{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:32:08Z","timestamp":1791765128783,"version":"4.3.4"},"reference-count":90,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>High-risk and locally advanced prostate cancer represents 20\u201325% of new diagnoses of prostate cancer and is associated with high rates of recurrence, morbidity, and mortality. The neoadjuvant window provides a unique opportunity for systemic control prior to definitive therapy with radical prostatectomy or radiotherapy (RT). Early trials with first-generation androgen deprivation therapy (ADT) achieved pathological downstaging but no survival benefit. In the 2000s, the advent of chemohormonal regimes using docetaxel provided excitement but mixed results tempered expectations and is now not recommended prior to surgery. Second-generation androgen receptor pathway inhibitors (ARPIs) combined with ADT have demonstrated significant survival benefit in metastatic prostate cancer and are currently being evaluated in large phase III trials in the neoadjuvant setting. RT remains an alternative curative modality, and recent data highlights similar issues to surgery in eradicating micrometastatic disease despite excellent local control. This has driven parallel efforts to evaluate intensified systemic therapy in the pre-RT\/neoadjuvant settings. In addition to the excitement surrounding ARPIs, radioligand therapy, such as [177Lu]Lu-PSMA-617 has shown promise in the neoadjuvant setting and continues to be investigated. Future research aims to incorporate genomic and molecular factors to enable personalised neoadjuvant therapies by identifying damage immunologically responsive subtypes that may derive greater benefit from immune-directed therapies in the peri-operative setting. This narrative review synthesises current evidence for neoadjuvant therapies in high-risk prostate cancer and future directions.<\/jats:p>","DOI":"10.3390\/cancers18010065","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T16:41:19Z","timestamp":1766594479000},"page":"65","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neoadjuvant Therapies for Prostate Cancer\u2013Current Paradigms and Future Directions"],"prefix":"10.3390","volume":"18","author":[{"given":"Kieran","family":"Sandhu","sequence":"first","affiliation":[{"name":"Division of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, VIC 3000, Australia"},{"name":"University of Cambridge, Cambridge CB2 3PT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6234-3522","authenticated-orcid":false,"given":"Abdullah","family":"Al-Khanaty","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, VIC 3000, Australia"},{"name":"Department of Surgery, University of Melbourne, Austin Health, Melbourne, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hennes","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, VIC 3000, Australia"},{"name":"Hudson Institute of Medical Research, Monash University, Clayton, VIC 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, VIC 3000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin","family":"Dinneen","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, VIC 3000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0400-2647","authenticated-orcid":false,"given":"Carlos","family":"Delgado","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, VIC 3000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, VIC 3000, Australia"},{"name":"Department of Surgery, University of Melbourne, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia"},{"name":"EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, VIC 3002, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu S.","family":"Eapen","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, VIC 3000, Australia"},{"name":"Hudson Institute of Medical Research, Monash University, Clayton, VIC 3800, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, VIC 3000, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"Perera","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, VIC 3000, Australia"},{"name":"Department of Surgery, University of Melbourne, Austin Health, Melbourne, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00345-008-0250-7","article-title":"High-risk prostate cancer in the United States, 1990\u20132007","volume":"26","author":"Cooperberg","year":"2008","journal-title":"World J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2012.08.001","article-title":"Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study","volume":"63","author":"Rider","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Perera, M., Beech, B.B., De Jesus Escano, M., Gmelich, C., Yip, W., Boorjian, S.A., and Eastham, J.A. (2022). Neoadjuvant Systemic Therapy Prior to Radical Prostatectomy for Clinically Localized High-Risk Prostate Cancer. Front. Urol., 2.","DOI":"10.3389\/fruro.2022.864646"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.juro.2006.06.002","article-title":"Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer","volume":"176","author":"Zelefsky","year":"2006","journal-title":"J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.300.2.173","article-title":"Survival following primary androgen deprivation therapy among men with localized prostate cancer","volume":"300","author":"Albertsen","year":"2008","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-05-0299","article-title":"Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer","volume":"11","author":"Febbo","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0360-3016(01)01579-6","article-title":"Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate","volume":"50","author":"Pilepich","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(05)70348-X","article-title":"Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial","volume":"6","author":"Denham","year":"2005","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199707313370502","article-title":"Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin","volume":"337","author":"Bolla","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.18.01777","article-title":"Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide with or Without Abiraterone","volume":"37","author":"McKay","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S1743","DOI":"10.1016\/j.annonc.2025.09.102","article-title":"LBA86 Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)","volume":"36","author":"Nguyen","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1200\/JCO.2022.40.16_suppl.5084","article-title":"Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC)","volume":"40","author":"Sandler","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","article-title":"Administering [(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1\/2 Study","volume":"85","author":"Eapen","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to Advanced Prostate Cancer: AUA\/SUO Guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41568-020-00300-6","article-title":"Cancer progression and the invisible phase of metastatic colonization","volume":"20","author":"Klein","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/annonc\/mdn386","article-title":"The effects of surgery on tumor growth: A century of investigations","volume":"19","author":"Demicheli","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer","volume":"83","author":"Devos","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"TPS5100","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5100","article-title":"PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC)","volume":"37","author":"Taplin","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/cncr.35170","article-title":"Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial","volume":"130","author":"McKay","year":"2024","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1200\/JCO.2022.40.6_suppl.224","article-title":"Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP","volume":"40","author":"Fleshner","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy with or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S673","DOI":"10.1016\/j.annonc.2021.08.1159","article-title":"646TiP A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse: The PEACE 2 trial from Unicancer","volume":"32","author":"Blanchard","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"TPS353","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS353","article-title":"A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1\/2 gene alterations (NePtune)","volume":"42","author":"McKay","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0022-5347(05)65971-X","article-title":"Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects","volume":"166","author":"Gleave","year":"2001","journal-title":"J. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.euo.2022.09.002","article-title":"Neoadjuvant (177)Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial","volume":"6","author":"Golan","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"ref_31","unstructured":"(2025, August 01). Phase II Study of Neoadjuvant Lu-177-PSMA-617 in Patients with High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06798558."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","article-title":"Neoadjuvant enoblituzumab in localized prostate cancer: A single-arm, phase 2 trial","volume":"29","author":"Shenderov","year":"2023","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0090-4295(98)00616-5","article-title":"CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results","volume":"53","author":"Klotz","year":"1999","journal-title":"Urology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1159\/000020366","article-title":"4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer","volume":"38","author":"Schulman","year":"2000","journal-title":"Eur. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1464-410X.2002.02982.x","article-title":"Three-month neoadjuvant hormonal therapy before radical prostatectomy: A 7-year follow-up of a randomized controlled trial","volume":"90","author":"Aus","year":"2002","journal-title":"BJU Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0022-5347(05)65393-1","article-title":"The Lupron Depot Neoadjuvant Prostate Cancer Study Group. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results","volume":"167","author":"Soloway","year":"2002","journal-title":"J. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0022-5347(01)67068-X","article-title":"Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group","volume":"154","author":"Elgamal","year":"1995","journal-title":"J. Urol."},{"key":"ref_38","first-page":"CD006019","article-title":"Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer","volume":"2006","author":"Kumar","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2008.08.002","article-title":"A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma","volume":"35","author":"Shelley","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2003.11.023","article-title":"Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02","volume":"21","author":"Hanks","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(22)00190-5","article-title":"High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01\/05): 10-year results of a phase 3 randomised, controlled trial","volume":"23","author":"Zapatero","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1158\/1078-0432.CCR-05-0525","article-title":"Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer","volume":"11","author":"Titus","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","article-title":"A hormone-DNA repair circuit governs the response to genotoxic insult","volume":"3","author":"Goodwin","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1158\/0008-5472.CAN-15-0892","article-title":"Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation","volume":"75","author":"Spratt","year":"2015","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","unstructured":"(2015). The Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell, 163, 1011\u20131025."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management","volume":"208","author":"Eastham","year":"2022","journal-title":"J. Urol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1158\/0008-5472.CAN-11-1417","article-title":"Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer","volume":"71","author":"Darshan","year":"2011","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1200\/JCO.18.02158","article-title":"Effect of Chemotherapy with Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial","volume":"37","author":"Rosenthal","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.juro.2008.04.012","article-title":"Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer","volume":"180","author":"Chi","year":"2008","journal-title":"J. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.urolonc.2007.04.003","article-title":"Phase I\/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10)","volume":"26","author":"Perrotti","year":"2008","journal-title":"Urol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clgc.2013.11.019","article-title":"Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma","volume":"12","author":"Marshall","year":"2014","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"100935","DOI":"10.1016\/j.adro.2022.100935","article-title":"Long-Term Outcomes of a Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image Guided Intensity Modulated Radiation Therapy for Localized High-Risk Prostate Adenocarcinoma","volume":"7","author":"McVorran","year":"2022","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Zhuang, J., Wang, Y., Zhang, S., Fu, Y., Huang, H., Lyu, X., Zhang, S., Marra, G., Xu, L., and Qiu, X. (2023). Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: A pooled analysis of two phase II trials. Front. Pharmacol., 14, (In English).","DOI":"10.3389\/fphar.2023.1217303"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ge, Q., Xu, H., Yue, D., Fan, Z., Chen, Z., Xu, J., Zhou, Y., Zhang, S., Xue, J., and Shen, B. (2022). Neoadjuvant Chemohormonal Therapy in Prostate Cancer Before Radical Prostatectomy: A Systematic Review and Meta-Analysis. Front. Oncol., 12, (In English).","DOI":"10.3389\/fonc.2022.906370"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"djv346","DOI":"10.1093\/jnci\/djv346","article-title":"A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer","volume":"108","author":"Ahearn","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study","volume":"39","author":"Chi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: A meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/pros.70000","article-title":"Transcriptomic Signatures of Monocyte-Derived Macrophages Associate with Androgen Receptor Pathway Inhibitor Progression in Prostate Cancer","volume":"85","author":"Sharifi","year":"2025","journal-title":"Prostate"},{"key":"ref_69","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Hupe, M.C., Philippi, C., Roth, D., K\u00fcmpers, C., Ribbat-Idel, J., Becker, F., Joerg, V., Duensing, S., Lubczyk, V.H., and Kirfel, J. (2018). Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis. Front. Oncol., 8, (In English).","DOI":"10.3389\/fonc.2018.00623"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.annonc.2025.07.003","article-title":"Final overall survival and safety analyses of the phase III PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Fizazi","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41585-024-00913-8","article-title":"Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer","volume":"21","author":"Eapen","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2174\/1381612023394089","article-title":"Immune modulation by ionizing radiation and its implications for cancer immunotherapy","volume":"8","author":"Friedman","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-Targeted \u03b1-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","article-title":"PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Sandhu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","article-title":"LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"41","author":"Sandhu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Kwon, W.A., and Joung, J.Y. (2025). Immunotherapy in Prostate Cancer: From a \u201cCold\u201d Tumor to a \u201cHot\u201d Prospect. Cancers, 17.","DOI":"10.3390\/cancers17071064"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Di Bello, F., Di Mauro, E., Colla Ruvolo, C., Creta, M., La Rocca, R., Celentano, G., Capece, M., Napolitano, L., Fraia, A., and Pezone, G. (2022). Immunotherapy for Urological Tumors on YouTube(TM): An Information-Quality Analysis. Vaccines, 11.","DOI":"10.3390\/vaccines11010092"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1756287220951404","DOI":"10.1177\/1756287220951404","article-title":"Immunotherapy in prostate cancer: Current state and future perspectives","volume":"12","author":"Handa","year":"2020","journal-title":"Ther. Adv. Urol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2016.08.037","article-title":"DNA Repair in Prostate Cancer: Biology and Clinical Implications","volume":"71","author":"Mateo","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","article-title":"B7-H3 as a Therapeutic Target in Advanced Prostate Cancer","volume":"83","author":"Guo","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Zhang, H., Koumna, S., Pouliot, F., Beauregard, J.M., and Kolinsky, M. (2021). PSMA Theranostics: Current Landscape and Future Outlook. Cancers, 13.","DOI":"10.3390\/cancers13164023"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"17588359231157632","DOI":"10.1177\/17588359231157632","article-title":"Status of PSMA-targeted radioligand therapy in prostate cancer: Current data and future trials","volume":"15","author":"Jang","year":"2023","journal-title":"Ther. Adv. Med. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/1\/65\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T07:58:06Z","timestamp":1766995086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/1\/65"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18010065"],"URL":"https:\/\/doi.org\/10.3390\/cancers18010065","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]}}}